Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
16.10
+1.17 (7.84%)
At close: Jun 26, 2026, 4:00 PM EDT
15.45
-0.65 (-4.04%)
After-hours: Jun 26, 2026, 7:40 PM EDT
Vor Biopharma Employees
Vor Biopharma had 76 employees as of December 31, 2025. The number of employees decreased by 83 or -52.20% compared to the previous year.
Employees
76
Change (1Y)
-83
Growth (1Y)
-52.20%
Revenue / Employee
n/a
Profits / Employee
-$11,619,474
Market Cap
872.39M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Phathom Pharmaceuticals | 371 |
| Omeros | 175 |
| ARS Pharmaceuticals | 159 |
| Solid Biosciences | 121 |
| Aura Biosciences | 113 |
| Odyssey Therapeutics | 100 |
| Annexon | 93 |
| Zevra Therapeutics | 61 |
VOR News
- 19 days ago - Vor Bio announces China NMPA approval for telitacicept - TheFly
- 19 days ago - Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China - GlobeNewsWire
- 19 days ago - Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China - GlobeNewsWire
- 24 days ago - Vor Biopharma Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 26 days ago - Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Vor Bio price target raised to $18 from $15 at Wedbush - TheFly
- 6 weeks ago - Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine - GlobeNewsWire